Free Trial
NASDAQ:ONC

BeOne Medicines Q1 2025 Earnings Report

BeOne Medicines logo
$267.04 -1.16 (-0.43%)
As of 12:11 PM Eastern
This is a fair market value price provided by Massive. Learn more.

BeOne Medicines EPS Results

Actual EPS
$1.22
Consensus EPS
-$0.71
Beat/Miss
Beat by +$1.93
One Year Ago EPS
N/A

BeOne Medicines Revenue Results

Actual Revenue
$1.12 billion
Expected Revenue
$1.12 billion
Beat/Miss
Missed by -$7.30 million
YoY Revenue Growth
N/A

BeOne Medicines Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

BeOne Medicines Earnings Headlines

BeOne Medicines (NASDAQ:ONC) CEO John Oyler Sells 1,949 Shares of Stock
Barclays Sticks to Its Buy Rating for BeOne Medicines (ONC)
How to play the Biggest IPO in stock market history!
SpaceX is eyeing a near-$2 trillion IPO valuation, and retail investors are already lining up - but early insiders and institutional holders have been sitting on positions for years and will exit the moment shares hit the market. Lance Ippolito has identified five stocks directly positioned to benefit from the SpaceX launch and the space investing wave it triggers, without the brutal IPO volatility. These picks carry none of the hype risk and all of the tailwind.tc pixel
Wolfe Research Sticks to Its Buy Rating for BeOne Medicines (ONC)
See More BeOne Medicines Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like BeOne Medicines? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BeOne Medicines and other key companies, straight to your email.

About BeOne Medicines

BeOne Medicines (NASDAQ:ONC) Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

View BeOne Medicines Profile